Mallinckrodt Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate Capsules and Launches Product Used to Treat Attention-Deficit/Hyperactivity Disorder (ADHD) ...Middle East

DUBLIN, Aug. 31, 2023 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKTQ), a global specialty pharmaceutical company, today announced that its Specialty Generics segment, operating as SpecGx LLC, received approval on August 25, 2023 from the United States Food and Drug Administration (FDA)...

Hence then, the article about mallinckrodt receives u s fda approval for lisdexamfetamine dimesylate capsules and launches product used to treat attention deficit hyperactivity disorder adhd was published today ( Thursday 31/08/2023 - 01:53 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Mallinckrodt Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate Capsules and Launches Product Used to Treat Attention-Deficit/Hyperactivity Disorder (ADHD) )

Also on site :

• Gold Star Distribution Inc., Issues Recall of Certain FDA-Regulated Products in Three States Including Drugs, Devices, Cosmetics, Human Foods, and Pet Foods
• ’Beverly Hills, 90210’s Jason Priestley Shares Bold Callout After ‘Worst’ Travel Experience
• Central African Republic election: Who’s running and what’s at stake?